A detailed history of Fox Run Management, L.L.C. transactions in Exelixis, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 43,111 shares of EXEL stock, worth $1.46 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
43,111
Previous 43,891 1.78%
Holding current value
$1.46 Million
Previous $986,000 13.39%
% of portfolio
0.26%
Previous 0.19%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.96 - $27.6 $17,128 - $21,528
-780 Reduced 1.78%
43,111 $1.12 Million
Q2 2024

Aug 13, 2024

BUY
$20.34 - $23.73 $90,472 - $105,551
4,448 Added 11.28%
43,891 $986,000
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $339,803 - $403,148
16,847 Added 74.56%
39,443 $935,000
Q4 2023

Feb 13, 2024

BUY
$19.25 - $24.13 $145,010 - $181,771
7,533 Added 50.01%
22,596 $542,000
Q3 2023

Nov 07, 2023

BUY
$19.04 - $22.74 $286,799 - $342,532
15,063 New
15,063 $329,000
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $216,569 - $287,600
12,418 New
12,418 $259,000
Q1 2022

May 10, 2022

SELL
$17.03 - $22.67 $349,983 - $465,891
-20,551 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$15.84 - $21.88 $325,527 - $449,655
20,551 New
20,551 $376,000
Q4 2020

Feb 08, 2021

SELL
$18.39 - $24.8 $199,733 - $269,352
-10,861 Closed
0 $0
Q3 2020

Oct 29, 2020

BUY
$20.67 - $26.94 $224,496 - $292,595
10,861 New
10,861 $266,000
Q2 2019

Jul 17, 2019

SELL
$18.93 - $24.75 $209,857 - $274,378
-11,086 Closed
0 $0
Q1 2019

Oct 17, 2019

SELL
$19.6 - $24.76 $287,982 - $363,798
-14,693 Reduced 57.0%
11,086 $264,000
Q4 2018

Jan 15, 2019

BUY
$13.65 - $21.8 $211,124 - $337,180
15,467 Added 149.99%
25,779 $507,000
Q3 2018

Oct 05, 2018

BUY
$15.87 - $22.4 $163,651 - $230,988
10,312 New
10,312 $183,000
Q4 2017

Jan 18, 2018

SELL
$24.23 - $30.93 $334,374 - $426,834
-13,800 Closed
0 $0
Q3 2017

Oct 23, 2017

BUY
$23.35 - $29.24 $322,230 - $403,512
13,800
13,800 $334,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.